[priyasaravanan_1406]

Recent happenings in Novartis AG - August 2013

Novartis AG is focused by the media for various happenings in favor of the organization started right from the beginning of the month August 2013.

Vaccine Menveo

The quadrivalent vaccine Menveo, a product of Novartis gets nod from FDA for its use in the age groups starting from 2 month old babies since 1st of August 2013.

Vaccine: Menveo

Against: Meningococcal disease

First quadrivalent vaccine: It is effective against the disease caused by four strains like A, C,Y and W 135 of the bacterium Neisseria meningitides.

Following this on 8th of August 2013 Novartis was accredited by CEO Rountable on cancer which is a NGO.

Nature of Accreditation: Global CEO cancer Gold standard Accreditation

Salient features of this Accreditation

This accreditation is granted based on the organization’s commitment to protect its employees from cancer which requires several initiatives by the organization like

Providing the employees a healthy work place

Guiding the employees to adopt good life style practices which keep them away from cancer

Making cancer detection and cancer screening techniques available to the employees through the organization and if detected with cancer providing them the best treatment

And Novartis is the first to get accredited for ensuring all the guidelines required to get accredited by the CEO Rountable Cancer.

The Vaccine Bexsero

Next comes in the news the approval of the Bexsero vaccine a Novartis product for its use in Australia which was announced on 15th of August 2013 and this vaccine entered the ARTG list through TGA.

Bexsero: Vaccine against the devastating disease MenB.

Who can get this vaccine?
From the age of 2 months and above

Clinical Trials: Proved the safety and efficiency of the vaccine. Done on average of eight thousand people which comprised of the individuals from infants to adults

Discussion on the importance of including this vaccine in the National immunization Program is underway.